Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences

Priyanka Vashisht, James Robert O'Dell

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Anti-TNF therapy has dramatically changed how we manage rheumatoid arthritis. There are many similarities among the five approved agents but also some important differences. Rheumatologists have 5 different options to choose from when they are ready to commence anti-TNF therapy. Although all block the TNF cytokine, there are important critical differences among them that affect their safety profile and clinical utility in certain scenarios. Unfortunately, there are no head to head trials to compare the different anti-TNF agents and none appear to be in the horizon. Areas covered: This article reviews the various clinical situations where it may be important to use a particular anti-TNF agent. The authors also give their expert opinion and future perspectives on the area. Expert opinion: Although there are many similarities among the five different TNFi that are clinically available, there are important clinical niches, where the limited data that are available, that clearly support the preferential use of a particular agent or class of agents. Assays or tests that allow us to find the ‘sweet spot’ of TNF inhibition at the level of each patient are long overdue.

Original languageEnglish (US)
Pages (from-to)989-999
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume17
Issue number8
DOIs
StatePublished - Aug 3 2017

Fingerprint

Expert Testimony
Rheumatoid Arthritis
Cytokines
Safety
Therapeutics
Assays
Rheumatologists

Keywords

  • Anti TNF
  • biologics
  • customization
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Not all TNF inhibitors in rheumatoid arthritis are created equal : important clinical differences. / Vashisht, Priyanka; O'Dell, James Robert.

In: Expert Opinion on Biological Therapy, Vol. 17, No. 8, 03.08.2017, p. 989-999.

Research output: Contribution to journalReview article

@article{4d982af4dfb845e49c75825397edcc57,
title = "Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences",
abstract = "Introduction: Anti-TNF therapy has dramatically changed how we manage rheumatoid arthritis. There are many similarities among the five approved agents but also some important differences. Rheumatologists have 5 different options to choose from when they are ready to commence anti-TNF therapy. Although all block the TNF cytokine, there are important critical differences among them that affect their safety profile and clinical utility in certain scenarios. Unfortunately, there are no head to head trials to compare the different anti-TNF agents and none appear to be in the horizon. Areas covered: This article reviews the various clinical situations where it may be important to use a particular anti-TNF agent. The authors also give their expert opinion and future perspectives on the area. Expert opinion: Although there are many similarities among the five different TNFi that are clinically available, there are important clinical niches, where the limited data that are available, that clearly support the preferential use of a particular agent or class of agents. Assays or tests that allow us to find the ‘sweet spot’ of TNF inhibition at the level of each patient are long overdue.",
keywords = "Anti TNF, biologics, customization, rheumatoid arthritis",
author = "Priyanka Vashisht and O'Dell, {James Robert}",
year = "2017",
month = "8",
day = "3",
doi = "10.1080/14712598.2017.1340453",
language = "English (US)",
volume = "17",
pages = "989--999",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - Not all TNF inhibitors in rheumatoid arthritis are created equal

T2 - important clinical differences

AU - Vashisht, Priyanka

AU - O'Dell, James Robert

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Introduction: Anti-TNF therapy has dramatically changed how we manage rheumatoid arthritis. There are many similarities among the five approved agents but also some important differences. Rheumatologists have 5 different options to choose from when they are ready to commence anti-TNF therapy. Although all block the TNF cytokine, there are important critical differences among them that affect their safety profile and clinical utility in certain scenarios. Unfortunately, there are no head to head trials to compare the different anti-TNF agents and none appear to be in the horizon. Areas covered: This article reviews the various clinical situations where it may be important to use a particular anti-TNF agent. The authors also give their expert opinion and future perspectives on the area. Expert opinion: Although there are many similarities among the five different TNFi that are clinically available, there are important clinical niches, where the limited data that are available, that clearly support the preferential use of a particular agent or class of agents. Assays or tests that allow us to find the ‘sweet spot’ of TNF inhibition at the level of each patient are long overdue.

AB - Introduction: Anti-TNF therapy has dramatically changed how we manage rheumatoid arthritis. There are many similarities among the five approved agents but also some important differences. Rheumatologists have 5 different options to choose from when they are ready to commence anti-TNF therapy. Although all block the TNF cytokine, there are important critical differences among them that affect their safety profile and clinical utility in certain scenarios. Unfortunately, there are no head to head trials to compare the different anti-TNF agents and none appear to be in the horizon. Areas covered: This article reviews the various clinical situations where it may be important to use a particular anti-TNF agent. The authors also give their expert opinion and future perspectives on the area. Expert opinion: Although there are many similarities among the five different TNFi that are clinically available, there are important clinical niches, where the limited data that are available, that clearly support the preferential use of a particular agent or class of agents. Assays or tests that allow us to find the ‘sweet spot’ of TNF inhibition at the level of each patient are long overdue.

KW - Anti TNF

KW - biologics

KW - customization

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85023617347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023617347&partnerID=8YFLogxK

U2 - 10.1080/14712598.2017.1340453

DO - 10.1080/14712598.2017.1340453

M3 - Review article

C2 - 28594252

AN - SCOPUS:85023617347

VL - 17

SP - 989

EP - 999

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -